Member Info for itsallamess

I think the FDA will give the go ahead for a new trial based on the info they have discovered since the last one.

Remember there is no real solution for ARDs and the only thing those poor people who have it is given corto steriods which Faron believe doesn't do much for them and counteracts the effectiveness of Traukamine.

As for a partner paying for further trials... Our CEO has stated that he intends to a partner to fund the trail...

Worth remembering from some interviews from early this year he said that interested party's were interested to be contacted once they find out what the issue was..

Wouldn't suprise me if we get a RNS very soon with news on fast track Traukamine trail and how it will be paid for by a partner

But the lack of rise today is not such a big thing

Over the past 12 months this share has risen 220.50p which equates to a 347.24% share rise

That means anyone who has an average of 80 100p a share are sitting on a 2 bagger already

Add to the fact the SP is pritty much holding and stable with each update

Hi pumpanddump

Not sure if your asking or asking others to find out, but most who have bought here should know the reason why the SP fell from 8plus quid

And that the issue for this has been fixed which is connected to the FDA meeting on traukamine right now

Reckon we will start to rise again after the initial MM games to get sellers

Looks like the few hundred share holders have sold up and moved on

Adiós guys

(NK cells are best known for killing virally infected cells, and detecting and controlling early signs of cancer)

(CD8+ T-cell or killer T cell) is a T lymphocyte (a type of white blood cell) that kills cancer cells, cells that are infected (particularly with viruses), or cells that are damaged in other ways)

(CD4+ cells, are a type of T cell that play an important role in the immune system, particularly in the adaptive immune system. They help the activity of other immune cells by releasing T cell cytokines. These cells help suppress or regulate immune responses.)

(Regulatory T (Treg) cells are found at elevated densities in many human cancers and are thought to be a major barrier to the generation of robust antitumor T cell responses)

"MATINS data suggests there may be an increased value to a Clevegen partnership with a wider number of partners. As announced on 1 November 2019, the Company is working hard to optimise the structure to capture the most value from any potential deal with the best possible partner"

"With the US IND now approved, in due course, we plan to file applications for Breakthrough status in the US and Prime status in Europe, further facilitating regulatory interactions during the development of Clevegen."

Google breakthough status;

"The FDA designed its Breakthrough Therapy status to give drugs intended to treat serious conditions a head start when they demonstrate a “substantial improvement” over medical solutions already available on the market"

The present finding potentially provides a method for choosing the best combination agent(s) to initiate treatment together with anti-Clever-1 therapy after observed changes in one or more checkpoint or activation marker expression.

"The Company has filed a related patent to protect this method"

We intend to carry out further analysis of other MATINS patients and aim to understand which combination of IO therapies would build the optimal host immune activation for various cancer types or individuals.

To have one single and safe treatment as early as possible would improve patient outcome

It's just about tweaking to get the best results.

Seems like they have figured out how to use clevergen as a one fits all treatment

Copper1

https://cslide.ctimeetingtech.com/immuno2019/attendee/confcal/session/calendar/2019-12-13

News on this soon.. could even be tomorrow AM!

"The Company is exploring various options for future API manufacturing. This termination has no impact on the currently on-going clinical advice process with FDA/EMA, which focuses on the structure of the next Traumakine clinical study"

And then this:

"The Company will have a face-to-face meeting with the FDA in early December 2019, which is expected to result in a written opinion of the FDA on the Company's clinical development plan for Traumakine"

And this:

"The Company currently envisages that a further Traumakine trial is likely to be funded through third party funding"

Website is gone all wonky donkey!

Looks like MMs are trying to bring us up to the Finns market price

Looks like the drop was overdone

The downer here is that they have to freebies to Ghana ( which sounds good if you are in ghana) but not great if you want to make money and production is very low...

Until they give a detailed account of how they will get production up this is a gamble as there could be a very serious reason production levels were so poor!

So basically they think the SP will balance out... Let's hope the balance is us going higher to met theirs!

But if course that's small fry in price when the next news drops

FDA approval for Traukamine trial
Clevegen update on tests in the US

Ectt..

OH and partner entry!

RNS logged for tomorrow morning announcing FDA approval for relaunch of Traumakine trial!

For the believers out there!

https://en.wikipedia.org/wiki/Clevegen

Clevegen has it's own wikipedia page

Looks like the 5000 shares could be the same buyer

60 grand spent allready!